Can ticagrelor be used as monotherapy for secondary prevention of acute coronary syndrome (ACS)?
Fuente:
Zenodo
Enregistré dans:
| Auteur principal: | |
|---|---|
| Format: | Recurso digital |
| Publié: |
Zenodo
2025
|
| Sujets: | |
| Accès en ligne: | |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
| _version_ | 1866901577083650048 |
|---|---|
| author | Tripdatabase |
| author_facet | Tripdatabase |
| contents | Ticagrelor monotherapy following short-term DAPT seems effective in reducing bleeding risk without increasing ischemic events in ACS patients post-PCI, but further research is necessary to fully validate its use outside of controlled trial settings. |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_17676363 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | Can ticagrelor be used as monotherapy for secondary prevention of acute coronary syndrome (ACS)? Tripdatabase ticagrelor monotherapy secondary prevention acute coronary syndrome ACS cardiology pharmacology long-term management Ticagrelor monotherapy following short-term DAPT seems effective in reducing bleeding risk without increasing ischemic events in ACS patients post-PCI, but further research is necessary to fully validate its use outside of controlled trial settings. |
| title | Can ticagrelor be used as monotherapy for secondary prevention of acute coronary syndrome (ACS)? |
| topic | ticagrelor monotherapy secondary prevention acute coronary syndrome ACS cardiology pharmacology long-term management |
| url | https://doi.org/10.5281/zenodo.17676363 |